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ㅋ
Recognizing nonerosive reflux disease (NERD) as a distinct presentation of gastroesophageal reflux disease (GERD) was one of 
the most important developments in the field of GERD in the last decade. Whilst the definition of NERD has not changed sig-
nificantly over the years, the disorder accounts for the majority of the GERD patients and those who failed proton pump in-
hibitor (PPI) treatment. Recent developments in NERD focused primarily on understanding the pathophysiology and natural 
history. The introduction of esophageal impedance + pH has led to the assessment of other forms of gastroesophageal reflux 
in causing NERD. Therapeutic modalities still focus on acid suppression, but there is growing recognition that other therapeutic 
strategies should be considered in NERD. 
(J Neurogastroenterol Motil 2010;16:8-21)
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Introduction
It has been demonstrated that 44% of the US population re-
port gastroesophageal reflux disease (GERD)-related symptoms 
at least once a month and 20% once a week.
1,2 Furthermore, due 
to the close relationship between GERD and body mass index 
(BMI), it is highly likely that the prevalence of GERD will close-
ly follow the increase in BMI that is expected in the future. 
Most of the patients with GERD fall into 1 of 2 categories: 
nonerosive reflux disease (NERD) or erosive esophagitis. The 2 
main phenotypes of GERD appear to have different pathophy-
siological and clinical characteristics. Furthermore, NERD and 
erosive esophagitis clearly diverge when it comes to response to 
antireflux treatment. NERD patients have a significantly lower 
response rate to proton pump inhibitor (PPI) therapy, and con-




NERD has been commonly defined as the presence of classic 
GERD symptoms in the absence of esophageal mucosal injury 
during upper endoscopy. The Genval workshop suggested that 
the definition of NERD should be reserved for individuals who 
satisfy the definition of GERD but who do not have either 
Barrett's esophagus or definite endoscopic esophageal mucosal 
breaks (erosion or ulceration).
5 We proposed that NERD should Nonerosive Reflux Disease (NERD) - An Update 
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Figure 1. A diagnostic algorithm for 
NERD and functional 
heartburn based on Rome 
III criteria.
10
be defined as the presence of typical symptoms of gastro-
esophageal reflux disease caused by intraesophageal reflux (acidic 
or weakly acidic), in the absence of visible esophageal mucosal in-
jury at endoscopy.
1 
Recently, the Montreal International Consensus defined 
GERD as a condition that develops when the reflux of stomach 
contents causes troublesome reflux-associated symptoms, and 
NERD was defined by the presence of these symptoms in the ab-
sence of esophageal mucosal breaks.
6 
Studies have shown that about 30-50% of NERD patients 
demonstrate esophageal acid exposure within the physiological 
range.
7 The Rome II Committee for Functional Esophageal 
Disorders considered these patients as having functional heart-
burn, defined as “episodic retrosternal burning in the absence of 
pathological gastroesophageal reflux, pathology-based motility 
disorders, or structural explanations.”
8 This subgroup was fur-
ther divided into 2 subgroups. The first subgroup included pa-
tients who demonstrated a close temporal relationship between 
their heartburn symptoms and acid reflux events, in spite of hav-
ing physiological range of esophageal acid exposure. This sub-
group accounts for up to 40% of patients with functional heart-
burn and has been termed the hypersensitive esophagus.
7 
Patients with hypersensitive esophagus demonstrate partial re-
sponse to PPI treatment.
9 In contrast, the other subgroup (up to 
60%) demonstrates lack of any correlation between heartburn ep-
isodes and acid reflux events. The Rome III Committee for 
Functional Esophageal Disorders redefined the functional heart-
burn group, and consequently NERD, by primarily incorporat-
ing the hypersensitive esophagus group and those patients with 
negative symptom association who are responsive to PPI treat-
ment back into the NERD group (Fig. 1).
10 
Epidemiology
Several early studies reported that about 50% of patients with 
heartburn were found to exhibit normal esophageal mucosa dur-
ing endoscopy.
11,12 There after, several community-based 
European studies of NERD patients found a much higher preva-
lence of up to 70%.
13,14 Galmiche et al.
15 assessed the efficacy of 
on-demand H2RA therapy in patients with GERD symptoms 
who were recruited from general practice clinics. A total of 423 
GERD patients were included in this study; and, of those, 71% 
met the criteria for NERD. Carlsson et al.
16 compared different 
treatment strategies for GERD at 36 primary care centers in 
Europe and Australia and noted that 49% of the 538 enrolled pa-
tients lacked esophageal mucosal breaks. 
In the United States, Robinson et al.
17 evaluated only sub-
jects who used antacids for symptomatic relief of heartburn. Of 
165 patients enrolled in this study, 53% had normal esophageal 
mucosa on upper endoscopy. In a recent population-based study, 
1,000 subjects with or without GERD-related symptoms from an 
adult population of 2 Swedish municipalities were randomly se-Tiberiu Hershcovici and Ronnie Fass
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lected to undergo an upper endoscopy. Of the patients with gas-
troesophageal reflux symptoms, only 24.5% were found to have 
erosive esophagitis.
18 More recently, Zagari et al. performed a 
large epidemiologic study in the general population of 2 villages 
in northern Italy and demonstrated a 23.7% (out of 1,033 sub-
jects) prevalence rate of patients with reflux symptoms at least 
twice a week. Of those patients with reflux symptoms, 75.9% 
were found to have a negative endoscopy.
19 
Overall, the results of old and recent epidemiologic studies 
investigating patients with GERD-related symptoms have sug-
gested that the prevalence of NERD in the general population is 
between 50% and 70%. Because the usage of proton pump in-
hibitors (PPIs) has become so widespread, it is likely that some of 
the recent studies that determined the prevalence of NERD have 
been contaminated by including healed erosive esophagitis sub-
jects as NERD patients. 
Natural History
Within the spectrum of GERD, the pathophysiological rela-
tionship between NERD and erosive esophagitis remains the 
subject of great debate.
20 The assumption that NERD and ero-
sive esophagitis represent 1 continuous disorder has been chal-
lenged by studies demonstrating differences in relation to epi-




24 performed a retrospective evaluation of patients 
with NERD. The authors followed 33 patients with NERD and 
documented abnormal esophageal pH monitoring for a period of 
3-6 months while on therapy with antacids, prokinetics or both. 
Five (15%) of the patients that remained symptomatic during 
therapy developed erosive esophagitis (unknown grading). 
Pretreatment pH testing results were not predictable of erosive 
esophagitis development. In this study, patients were treated 
from the time of admittance into the study, suggesting that some 
may have not been true NERD patients. Furthermore, the ob-
servation in the study that NERD patients rapidly progressed to 
develop erosive esophagitis after only a very short duration of fol-
low-up (3-6 months) may further support the conclusion that 
those who developed erosive esophagitis during the study period 
were likely healed erosive esophagitis patients that were falsely la-
beled as having NERD from the beginning. 
Kuster et al.
25 followed 109 patients with GERD, of whom 
33 had endoscopically documented erosive esophagitis. The au-
thors used a step-up approach in which patients initially received 
antacids and prokinetics, and if symptoms continued an H2RA 
was prescribed. Patients that did not respond to an H2RA were 
referred for antireflux surgery. At the 3-year follow-up, 109 pa-
tients were available for evaluation, and of those 52% required 
only antacids plus prokinetics to control their symptoms. At the 
6-year follow-up, 89 patients were available for evaluation, and of 
those 55% required only antacids plus prokinetics to control their 
symptoms. Regardless of therapy, only 2.7% of the NERD pa-
tients developed erosive esophagitis after 3 years and 3% after 6 
years of follow-up. Unlike Pace et al.,
24 this study provided lon-
ger duration of follow-up, and despite its limitations very few 
NERD patients progressed to develop esophageal mucosal 
injury. Isolauri et al.
26 conducted a longer duration follow-up 
(17-22 years, mean 19.5 years) of 60 patients with documented 
GERD. Patients received medical (50) or surgical (10) antireflux 
therapy as needed (no standardization). Of the 50 subjects that 
received only medical therapy, 30 had NERD and 20 erosive 
esophagitis at baseline. At follow-up, only 5 (17%) of the NERD 
patients progressed to develop erosive esophagitis (all to grade 1 
Savary-Miller). 
McDougall et al.
27 conducted a 10 year follow-up of 152 pa-
tients with typical GERD symptoms and grade 1-3 erosive 
esophagitis (modified Savary-Miller) documented during an up-
per endoscopy. Over 70% of the patients still had heartburn daily 
or at least weekly at follow-up. Patients reporting dysphagia un-
derwent repeat endoscopy, revealing 2 new benign peptic stric-
tures and 1 Barrett’s esophagus. However, because this was a 
survey study and patients were allowed to be on and off treatment 
ad libitum, it is difficult to interpret the findings. Furthermore, 
the presence of so-called “new Barrett’s esophagus” may well be 
an unrecognized Barrett’s mucosa that was present underneath 
esophageal inflammation. In another study, McDougall et al.
28 
performed a prospective follow-up of 101 GERD patients for a 
period of at least 32 months after initial assessment with pH test-
ing and an upper endoscopy. During follow-up, more than half of 
the patients were on a PPI or H2RA. Of the 17 subjects with 
NERD and abnormal pH testing, 4 (24%) developed erosive 
esophagitis while on H2RA. Again, the authors’ report in this 
study that 3 patients with erosive esophagitis developed Barrett’s 
esophagus may also represent an unrecognized Barrett’s mucosa 
that was present underneath the esophageal inflammation. 
Manabe et al.
29 followed 105 patients with mild erosive 
esophagitis (Los Angeles classification A and B) for a mean dura-
tion of 5.5 years. Only 10.5% of the patients progressed to higher 
grading (mostly Los Angeles grade C), and none have pro-Nonerosive Reflux Disease (NERD) - An Update 
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Figure 2. Proposed new paradigm for the natural course of 
NERD.
23
Table 1. The Largest Population-based Studies Assessing Progre-
ssion of NERD to Erosive Espophagitis
23
Study N Follow-up Progression
Labenz
32   3,894    2 years 25.5%
Sontag
35   2,306 7.6 years      0%
Bardhan
36 12,374  24 years   4.4%
gressed to Barrett’s esophagus. This study suggests that even 
within the different gradings of erosive esophagitis, there is very 
little progression over time. 
Two recent retrospective studies stand out in their findings 
about the natural course of GERD. Unlike the aforementioned 
studies as well as other more recently published articles (vide in-
fra), Pace et al.
30 have reported a 94% progression of NERD to 
erosive esophagitis. Using their original cohort of GERD sub-
jects,
24 the authors were able to endoscope 18 of 33 subjects. 
Seventeen (94%) were found to have esophageal mucosal in-
flammation (erosive esophagitis). The authors concluded that 
GERD is a chronic disease characterized by increasing severity in 
time, requiring protracted medical therapy. Although the authors 
provide only 2 endoscopies (index and follow-up), they con-
cluded that almost all NERD patients are destined to progress 
over time to develop erosive esophagitis, regardless of the extent 
of their esophageal acid exposure.
31 The study does not provide 
evidence of increased severity in gastroesophageal reflux that par-
allels the new endoscopic findings. In contrast to the previous 
study, Labenz et al. have recently proposed a highly complex 
model to describe the natural course of GERD.
32 Using the 
ProGERD (progression of gastroesophageal reflux disease) da-
tabase, the authors evaluated progression or regression in 
GERD. Interestingly, the study demonstrated significant pro-
gression and regression after 2 years of follow-up.
31 The authors 
showed that 24.9% of the NERD patients progressed to develop 
low-grade erosive esophagitis (Los Angeles classification grades 
A and B), and 0.6% developed severe erosive esophagitis (Los 
Angeles classification grades C and D). Surprisingly, 50.4% of 
those with grades C and D and 61.3% with grades A and B re-
gressed to NERD. Again, the study provides only 2 endoscopies 
(index and follow-up), and thus the durability of the described 
esophageal mucosal findings is unknown. Furthermore, 73% of 
the subjects in this study had taken antireflux medications, and 
61% had visited a physician.
33 The study suggests for the first 
time that patients move freely and in large numbers from NERD 
to erosive esophagitis and back again. 
Garrido Serrano et al. followed 692 GERD patients over a 
period of 6 years and prospectively assessed progression or re-
gression along the spectrum.
34 The authors found that patients 
with NERD (50% of the sample) did not develop erosive esoph-
agitis and those with erosive esophagitis remained within the 
stage of the initial diagnosis. Sontag et al.
35 evaluated 4,633 pa-
tients undergoing endoscopy for reflux symptoms over a mean 
follow-up period of 7.6 years. The patients received antireflux 
medications, but treatment regimens were not standardized for all 
patients. The authors were unable to document progression of 
NERD along the spectrum. Bardhan et al. provided the longest 
and largest natural history data evaluating 12,374 GERD pa-
tients over a period of 24 years.
36 The authors were able to docu-
ment only 4.4% progression to erosive esophagitis among the 
NERD patients. 
Overall, the currently available natural course studies suggest 
that lack of progression is more common than progression along 
the spectrum for patients with NERD (Table 1). Most im-
portantly, there is no evidence that NERD patients may progress 
over time to develop Barrett’s esophagus. 
Fass and Ofman
22 proposed a novel paradigm suggesting 
that GERD patients exhibit 3 phenotypic presentations: NERD 
erosive esophagitis, and Barrett’s esophagus. The vast majority of 
NERD and erosive esophagitis patients remain within their re-
spective GERD groups throughout their lifetime. This new para-
digm proposes that the genetic makeup of each individual subject 
exposed to similar environmental factors may ultimately de-
termine the specific phenotypic presentation of GERD (Fig. 
2).
22,23 In other words, GERD phenotypes once determined re-
main true to form.
35,37 
Pathophysiology
Current concepts in the pathophysiology of NERD involve Tiberiu Hershcovici and Ronnie Fass
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Table 2. The Extent of the Overlap of Esophageal Acid Exposure 
(time pH < 4) among the Different GERD Groups
40
Group Total  Upright Recumbent
compared (%) (%)  (%)
BE, EE 47.8 40.7 24
BE, NERD 31.6 37.5 20.8
EE, NERD 47.4 64.7 81.8
BE, Barrett’s esophagus; EE, erosive esophagitis.
peripheral factors (luminal, mucosal, and sensory afferents) as 
well as central (psychological, stress, sleep, etc.). 
Overall, there is no difference in gastric acid output between 
NERD patients and those with erosive esophagitis.
38 The level of 
esophageal acid exposure in NERD patients has been examined 
by Martinez et al.
39 The authors demonstrated that only 45.1% of 
NERD patients had an abnormal pH test compared with 75% of 
patients with erosive esophagitis and 92.9% of patients with 
Barrett's esophagus. The mean recorded number of acid reflux 
events was 95.3 in NERD versus 139.7 in those with erosive 
esophagitis. Furthermore, patients with NERD had the lowest 
esophageal acid exposure profile (pH ＜ 4) in % total, re-
cumbent, and upright time as compared to the other GERD 
groups. In fact, the mean esophageal acid exposure values were 
only mildly abnormal.
40 Unlike patients with erosive esophagitis 
and Barrett’s esophagus who demonstrate intense acid exposure 
in the very distal portion of the esophagus, NERD patients have 
very little variation in esophageal acid exposure distribution 
throughout the esophagus (total and recumbent).
41 Shapiro et al. 
have shown a marked overlap in acid exposure between NERD 
patients and those with erosive esophagitis and even those with 
Barrett’s esophagus (Table 2).
40 This study suggests that other 
environmental and genetic factors play an important role in dis-
ease presentation. 
Adachi et al. have demonstrated that NERD patients had 
significantly lower nighttime esophageal acid exposure as com-
pared to patients with grade C and D erosive esophagitis.
42 
Dickman et al. have demonstrated that the esophageal acid ex-
posure pattern during sleep is similar among the different 
GERD groups.
43 NERD patients with abnormal pH test had 
similar level of esophageal acid exposure during sleep as patients 
with erosive esophagitis. Esophageal acid exposure was the high-
est at the beginning of sleep and markedly dropped toward the 
middle of the sleep period. 
Several luminal factors were found to be predictors of a 
sensed acid reflux event as compared to a non-sensed acid reflux 
event (using impedance + pH sensor), and they include prox-
imal migration of an acid reflux event, larger pH drops, lower 
pH nadir, larger volume and acid clearance time, preceding 
higher esophageal cumulative acid exposure time, and presence 
of gas in the refluxate.
44,45 Recently, Schey et al. have shown that 
NERD patients demonstrated the highest number of acid reflux 
events before sensed reflux event as compared with other heart-
burn groups. This suggests that prior sensitization is needed for 
an acid reflux to be perceived in NERD patients who demon-
strated a lower acid exposure compared with erosive esophagitis 
patients.
46 Proximal esophageal migration of a reflux event has 
been shown to be an important predictor of symptom generation 
in NERD patients as well as other GERD groups, regardless if 
the reflux is acidic or weakly acidic.
47 The underlying mechanism 
for this phenomenon is unknown. Some have stipulated that it is 
likely due to summation effect (the higher the reflux, the more 
esophageal pain receptors are sensitized) or increased sensitivity 
of the proximal portion of the esophagus to either chemical or 
mechanical stimuli. 
The role of nonacid reflux in NERD was recently assessed by 
esophageal impedance-pH monitoring in 150 NERD patients. 
NERD patients had more reflux episodes (acid and nonacid) as 
compared to controls. A total of 42% of patients had abnormal 
esophageal acid exposure as compared to controls. In the sub-
group of patients with normal acid exposure, 15% had positive 
symptom-association probability (SAP) for acid, 12% for non-
acid reflux, and 5% for both.
48 A recent study conducted in a 
small group of normal subjects has demonstrated that acidic or 
weakly acidic solutions can result in the development of dilated 
intercellular spaces (DIS).
49 That suggests that NERD patients 
are likely to develop similar mucosal abnormalities from both 
types of gastroesophageal reflux. 
There are very limited data concerning the role of bile reflux 
in symptom generation of patients with NERD. The mean fast-
ing gastric bile acid concentration in NERD patients is similar to 
healthy controls. Additionally, combined acid and duodenogas-
troesophageal reflux, which correlates with severity of mucosal 
involvement in GERD, has been documented in only 50% of 
NERD patients compared with 79% of erosive esophagitis 
patients.
50 
Physiological studies in patients with NERD have revealed 
minimal esophageal abnormalities. These patients have a slightly 
higher rate of primary peristalsis failure, defined by non-trans-
mitted contractions or peristaltic contractions that do not traverse Nonerosive Reflux Disease (NERD) - An Update 
13 Vol. 16, No. 1 January, 2010 (8-21)
the entire esophageal body as compared to normal controls.
51 
Recently, it has been demonstrated that the rate of triggering sec-
ondary peristalsis in patients with NERD was significantly lower 
than in normal controls. However, when secondary peristalsis did 
occur in NERD patients, there was no difference in amplitude 
and velocity when compared to normal controls.
51 However, the 
abnormality in secondary peristalsis may explain the overall ho-
mogeneous distribution of acid reflux that was observed by 
Dickman et al.
41 Distal amplitude contractions, as well as mean 
lower esophageal resting pressure, are mildly reduced in NERD 
patients as compared with normal subjects. Resting lower esoph-
ageal sphincter pressure is rarely below 10 mmHg.
20 In contrast, 
25% of patients with mild erosive esophagitis and 48% of those 
with severe erosive esophagitis demonstrate peristaltic dysfunc-
tion. The mean resting lower esophageal sphincter pressure is 
significantly lower in patients with erosive esophagitis as com-
pared to those with NERD.
20,38 
Hiatal hernia occurs in only the minority of NERD patients. 
Cameron et al.
52 compared hiatal hernia rates in patients with 
NERD versus those with erosive esophagitis and demonstrated 
that 29% of the NERD patients had hiatal hernia as compared 
with 71% of those with erosive esophagitis. The absence of dia-
phragmatic hernia suggests that transient lower esophageal 
sphincter relaxation is likely the predominant mechanism for gas-
troesophageal reflux in most of the NERD patients.
53 
In most NERD patients, DIS (with a cut-off values of more 
than 0.56 nm) could be identified using electron micrograph.
54 
The occurrence of DIS in NERD is attributed to esophageal mu-
cosal exposure to gastroesophageal reflux and possibly even other 
stimuli.
3 Mastracci et al. have demonstrated that Ki 67 nuclear 
antigen, which is expressed by proliferating cells and provides an 
objective way to measure the regeneration of squamous epi-
thelium, can serve as a marker that can distinguish NERD pa-
tients from normal controls.
55 
Visceral hypersensitivity has been considered to be an im-
portant pathophysiological mechanism in NERD. Three broad 
mechanisms are believed to underlie visceral hypersensitivity: pe-
ripheral sensitization, central sensitization, and psychoneur-
oimmune interactions.
56 
In general, assessment of esophageal sensitivity in NERD 
patients has yielded evidence for reduced perception thresholds 
for painful stimuli. However, results are difficult to compare due 
to different sensory testing protocols as well as stimuli. 
Furthermore, many studies evaluate so-called “NERD patients” 
without excluding the functional heartburn group. 
Miwa and colleagues have specifically evaluated stimulus re-
sponse functions to acid in patients with NERD, as compared to 
other GERD groups, using an acid perfusion paradigm.
57 The 
authors demonstrated that NERD patients had lower perception 
thresholds for pain, especially as compared to normal controls, 
but also as compared to those with erosive esophagitis and 
Barrett’s esophagus. In a subsequent study, the authors con-
firmed their previous results but also noted that NERD patients 
were more sensitive to saline than subjects with erosive 
esophagitis.
58 The authors concluded from this study that 
NERD patients display a more general esophageal hyper-
sensitivity that is not limited to acidic stimuli only. Even when 
compared to functional heartburn, NERD patients with abnor-
mal pH testing demonstrated lower perception thresholds for 
pain using a similar acid perfusion paradigm.
59 It has been pro-
posed that the functional heartburn group, as compared to 
NERD patients, is a heterogeneous group composed of those 
with esophageal hypersensitivity to acid and others who show no 
sensitivity to any chemical stimuli. An interesting study has dem-
onstrated that the proximal esophagus in NERD patients is more 
sensitive to acid perfusion as compared to the distal esophagus.
60 
The study may provide 1 of the explanations for the strong rela-
tionship between proximal esophageal migration of acid reflux 
and symptoms generation in GERD patients. 
Mechanical and thermal stimulation of the esophagus were 
also assessed in NERD patients. In a study by Reddy et al., the 
authors used a multimodal stimulation probe to assess pain 
evoked by either thermal or mechanical stimuli.
61 NERD pa-
tients demonstrated increased esophageal sensitivity only to heat 
stimuli but not to cold or mechanical stimuli as compared to nor-
mal controls. However, other studies have also demonstrated an 
increased sensitivity to mechanical stimuli (balloon distention) in 
NERD patients as compared to the other GERD groups.
62
Several receptors have been identified as mediating esoph-
ageal hypersensitivity due to acid including up-regulation of acid 
sensing ion channels, increased expression of TRPV1 receptors 
(transient receptor potential vanilloid type 1), and prostaglandin 
E-2 receptor (EP-1).
63,64 
Various central mechanisms have also been shown to influ-
ence processing of afferent signals at the brain level.
65 
Psychological stresses and emotional perturbation have been 
demonstrated to potentiate perception of intraesophageal stimuli. 
By using dichotomous listening, Fass et al. demonstrated that 
acute laboratory stress increased sensitivity to intraesophageal 
acid perception in patients with either erosive or nonerosive reflux Tiberiu Hershcovici and Ronnie Fass
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Figure 3. The “Fass and Tougas” 




Figure 4. The “Barlow and Orlando” 
suggested model for heart-




66 The authors also noted that the increase in perceptual 
responses to acid was associated with greater emotional response 
to the stressor. Sleep deprivation has also been shown to induce 
esophageal hypersensivity to acid perfusion, although the study 
was carried out only in patients with erosive esophagitis.
67 
Models for Heartburn in NERD
Several models for heartburn in NERD patients have been 
proposed. Fass and Tougas suggested that intraesophageal stim-
uli, either pathologic or physiologic, may lead to symptoms in 
NERD patients. In their model, the authors emphasized the role 
of central (through brain-gut interactions) and peripheral (not 
esophageal) mechanisms in modulating perception of intra-
esophageal stimuli (Fig. 3).
68 
Barlow and Orlando proposed the following model to explain 
the pathophysiology of NERD: DIS enables the diffusion of re-
fluxed gastric acid into the intercellular spaces. Then, acid reach-Nonerosive Reflux Disease (NERD) - An Update 
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Figure 5. The “Ang, Sifrim and Tack”
model for heartburn in 
NERD.
70
es and activates chemosensitive nociceptors whose signals are 
transmitted via the dorsal horn of the spinal cord to the brain for 
symptoms perceptions (Fig. 4).
69 
The “Ang, Sifrim and Tack” model combines many of the 
concepts put forth by the 2 previously mentioned conceptual 
models (Fig. 5).
70 This model emphasizes the value of esophageal 
hypersensitivity to both mechanical and chemical stimuli. 
Clinical Characteristics
A large study involving 25 centers in Denmark and Sweden 
reported on 424 patients with troublesome heartburn associated 
with NERD. The mean age of the population was 50 yr; 58% 
were female; only 21% were smokers; 45% were active alcohol 
users; 53% had more than a 5-year history of heartburn; and only 
37% had hiatal hernia documented during upper endoscopy.
71 
Carlsson et al.
16 compared the clinical characteristics of patients 
with NERD and those with erosive esophagitis. In the NERD 
group, 60% were female; the mean age was 49 yr; mean weight 
was 80.5 kg for males and 69.5 kg for females; 23% were smok-
ers; 59% were alcohol consumers; 80% had symptom duration 
longer than 12 months; 29% had hiatal hernia; and 34% were 
positive for Helicobacter pylori. The erosive esophagitis group was 
similar to the NERD group in mean age, smoking and alcohol 
consumption, prevalence and duration of heartburn, and status of 
Helicobacter pylori infection. However, there were more males 
(59%) in the erosive esophagitis group, increased prevalence of 
hiatal hernia (56%), and increased weight of both males and fe-
males (86 kg and 76 kg, respectively). 
Increase in body mass index (BMI) is associated with in-
creased risk for having erosive esophagitis.
72 Furthermore, obese 
patients (BMI ≥ 30 kg/m
2) demonstrate a higher prevalence of 
erosive esophagitis (26.5%) as compared to normal-weight sub-
jects (9.3%).
73 The effect of metabolic risk factors on the natural 
history of GERD was quantified in a large population under-
going repeated endoscopy. Being male, smoking, or having meta-
bolic syndrome independently increased the likelihood of pro-
gression from NERD to erosive esophagitis.
74 
Psychological comorbidities in GERD patients have been 
shown to predict the presence of GERD-related symptoms re-
gardless of the presence or absence of esophageal mucosal 
injury.
75-77 Patients with higher emotional sensitivity or neuroti-
cism complain more frequently of GERD symptoms such as 
heartburn. However, studies did not find a specific correlation 
between psychological comorbidity and esophageal mucosal 
damage or extent of esophageal acid exposure.
78Tiberiu Hershcovici and Ronnie Fass
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A recent study by Wu et al.
79 evaluated the clinical character-
istics of patients with NERD in comparison to those with erosive 
esophagitis. Each patient underwent endoscopy, esophageal 
manometry, acid perfusion test, and ambulatory 24-hour esoph-
ageal pH monitoring. The authors found that NERD patients 
had a significantly higher prevalence of functional bowel dis-
orders such as functional dyspepsia and irritable bowel syndrome, 
psychological disorders, and positive acid perfusion test. Patients 
with erosive esophagitis were characterized by higher prevalence 
of hiatal hernia, greater esophageal acid exposure, and more 
esophageal dysmotility. 
Irritable bowel syndrome (IBS) like symptoms as well as dys-
pepsia-like symptoms are very commonly reported by NERD 
patients.
79,80 However, the association with functional bowel 
symptoms is not distinctive to NERD and is also very common in 
erosive esophagitis patients. These symptoms were demonstrated 
to independently determine reflux symptoms severity in NERD 
patients as compared to normal controls.
81 In a study comparing 
NERD and functional heartburn patients, bowel symptoms were 
similarly scored by both groups, but the severity of reflux symp-
toms was independently associated with the bowel symptoms.
82 
Clinical studies have demonstrated that heartburn severity 
and intensity are similar in patients with erosive esophagitis and 
those with NERD.
83 Additionally, the impact of heartburn se-
verity on patients’ quality of life was similar in both GERD 
groups as well.
16,84 Furthermore, sleep dysfunction is similar be-
tween patients with NERD and those with erosive esophagitis.
85 
Diagnosis
Upper endoscopy is the most sensitive diagnostic tool for as-
sessing GERD-related esophageal mucosal injury such as ero-
sions, ulceration, stricture, Barrett’s esophagus, and others. 
However, uncertainty in detecting mucosal breaks and in de-
scribing their severity can lead to inconsistency among different 
endoscopists. This is particularly essential in diagnosing NERD 
because of the need to demonstrate normal endoscopic examina-
tion of the esophageal mucosa. However, several recent studies 
using high resolution magnification endoscopy demonstrated the 
presence of minimal mucosal changes at the squamocolumnar 
junction of GERD patients with normal conventional upper 
endoscopy. The changes included vascular injection or vascular 
spots above the Z-line, villous mucosal surface, mucosal islands, 
and microerosions.
86 Others have added Lugol chromoendo-
scopy to further evaluate NERD patients for minimal esophageal 
changes at the squamocolumnar junction. Visible unstained 
streaks by Lugol chromoendoscopy were considered indicative of 
mucosal injury (as was further substantiated by biopsy).
87 
Recently, narrow-band imaging (NBI) was introduced for 
better visualization of mucosal and microvascular patterns at the 
esophagogastric junction of NERD patients with normal 
endoscopy. This technique utilizes spectral narrow band filters 
and enables imaging of superficial tissue structures such as capil-
lary and mucosal patterns without the use of dye. Sharma et al. 
demonstrated that the presence of microerosions and increased 
vascularity at the squamocolumnar junction were the best pre-
dictors for GERD diagnosis. These results were further con-
firmed when subgroup analysis of NERD and erosive esoph-
agitis was compared separately to controls. Although the interob-
server agreement for various NBI findings was very good, the in-
traobserver agreement was modest.
88 A subsequent study demon-
strated that the intra-and interobserver reproducibility in grading 
esophageal mucosal changes could be improved when NBI was 
applied together with conventional imaging. This additional ben-
efit appeared to derive from better depiction of small erosions.
89 
As a result of the aforementioned and other studies, the term 
“minimal change esophagitis” was introduced, and further stud-
ies claimed that these mucosal changes can be detected in many 
patients with NERD.
90 Consequently, some authors went further 
and proposed that NERD patients with normal conventional en-
doscopy, but with minimal changes at the squamocolumnar junc-
tion during magnification endoscopy, chromoendoscopy or NBI, 
should be considered as having erosive esophagitis. However, 
there were no attempts to correlate minimal mucosal changes with 
esophageal physiological abnormalities and to show that these pa-
tients are truly closer to erosive esophagitis than to NERD. In 
addition, the clinical implications of these findings remain to be 
elucidated. One study has already demonstrated that patients 
with the so-called “minimal change esophagitis” have different 
physiological characteristics than patients with erosive 
esophagitis.
90 Furthermore, concerns have been raised about the 
inter-and intraobserver variability of these minute lesions. Thus, 
the value of documenting minimal mucosal changes in NERD 
patients is presently unclear. Furthermore, the yield of identify-
ing these lesions should be weighed against the cost of the needed 
equipment and the availability of more economical strategies to 
handle these patients. 
Distinguishing NERD patients from those with eosinophilic 
esophagitis has become a major area of interest in the past few 
years. Whilst most of those with classic GERD symptoms are un-Nonerosive Reflux Disease (NERD) - An Update 
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likely to have eosinophilic esophagitis, it is those who appear to 
have some of the clinical and anatomic features of eosinophilic 
esophagitis who have been the focus of investigation if GERD is 
the direct underlying cause.
91 Recently, Dellon et al. compared 
clinical, endoscopic, and histologic findings between eosinophilic 
esophagitis and GERD.
92 Unconditional logistic regression was 
performed to develop a model to predict eosinophilic esophagitis, 
and receiver operator characteristic curves were constructed. The 
authors found that, as compared with GERD, features that in-
dependently predict eosinophilic esophagitis included younger 
age, dysphagia, food allergy, esophageal rings, linear furrows, 
white plaques or exudate, absence of hiatal hernia, a higher max-
imum eosinophil count, and the presence of eosinophil de-
granulation in the biopsy specimen. The area under the curve for 
this model was 0.934. 
Ambulatory 24-hour esophageal pH monitoring is essential 
for diagnosing NERD, especially after the recent introduction of 
the new definitions for functional heartburn by the Rome III 
Committee for Functional Esophageal Disorders.
10 However, 
the test is not commonly done in practice, and response to PPI 
treatment has been used instead to identify the functional heart-
burn patients.
93-95 Esophageal impedance + pH has been used 
extensively to primarily study patients who failed PPI treatment. 
By using this technique, patients who are not responsive to PPI 
treatment (up to twice daily) have more than a 50% chance of 
having functional heartburn.
96 However, the role of impedance 
+ pH in nontreated GERD patients, and more specifically in 
those with NERD, is likely to be very limited.
3 
Treatment
PPIs are currently considered the most effective and safe 
therapeutic modality for GERD. In clinical trials, these agents 
have consistently been demonstrated to be more effective than 
any other acid-suppressant agent in healing erosive esophagitis 
and relieving GERD-related symptoms. The superior efficacy of 
PPIs is also observed in NERD patients. In a recent meta-analy-
sis, van Pinxteren et al. demonstrated that the relative risk (RR) 
for heartburn remission in placebo-controlled trials of patients 
with NERD was 0.68 (95% CI: 0.59-0.78) for PPIs versus pla-
cebo and 0.84 (95% CI: 0.74-0.95) for H2RA versus placebo.
97 
The relative risk for PPIs versus H2RAs was 0.74 (95% CI: 
0.53-1.03). 
A number of studies evaluated the efficacy of PPIs in 
NERD patients. In a multicenter, randomized, double-blind 
study, omeprazole 20 mg once daily was compared with placebo 
in controlling symptoms of 209 patients with NERD.
98 After 4 
weeks of therapy, 57% of patients in the omeprazole group were 
free of heartburn, 75% were free of acid regurgitation, and 43% 
were completely asymptomatic. In another study, NERD pa-
tients were randomized to omeprazole 20 mg/day, omeprazole 10 
mg/day, or placebo.
13 The study authors found that at 4 weeks, 
46% of patients treated with omeprazole 20 mg/day, 31% treated 
with omeprazole 10 mg/day, and 13% of those who received pla-
cebo reported complete relief of heartburn. Miner et al. enrolled 
203 patients with NERD who were randomized to either rabe-
prazole 20 mg once daily or placebo. After 4 weeks, 56.7% of the 
patients receiving rabeprazole reported satisfactory symptom re-
lief when compared with 32.2% of those receiving placebo (p＜ 
0.008).
99 A recent study that utilized the wireless pH capsule has 
demonstrated that PPIs can normalize esophageal acid exposure 
in patients with NERD within 48 hours after initial admini-
stration.
100 
In general, the proportion of NERD patients responding to a 
standard dose of PPI is approximately 20-30% lower than what 
has been documented in patients with erosive esophagitis. In a 
systematic review of the literature, PPI symptomatic response 
pooled rate was 36.7% (95% CI: 34.1-39.3) in NERD patients 
and 55.5% (95% CI: 51.5-59.5) in those with erosive 
esophagitis.
101 Therapeutic gain was 27.5% in NERD as com-
pared with 48.9% in erosive esophagitis. Moreover, patients with 
NERD demonstrate a close relationship between response to 
PPI therapy and degree of esophageal acid exposure. The greater 
the distal esophageal acid exposure, the higher the proportion of 
NERD patients reporting symptom resolution.
13 This is the op-
posite of what has been observed in patients with erosive esoph-
agitis, where increased esophageal inflammation has been asso-
ciated with lower response rate to PPI once daily. Patients with 
NERD also demonstrate longer lag time to sustained symptom 
response when compared to patients with erosive esophagitis (2 to 
3-fold). Furthermore, patients with NERD demonstrate similar 
symptomatic response to half and full standard dose of PPI,
102 
unlike patients with erosive esophagitis who demonstrate an in-
cremental increase in healing and symptom resolution. In 1 
study, the time to first and sustained relief of reflux symptoms 
during PPI treatment was assessed by the ReQuest
TM ques-
tionnaire in NERD patients. Both pantoprazole (20 mg/day) and 
esomeprazole (20 mg/day) have been shown to provide a similar 
median time to first symptom relief (2 days) and to sustained 
symptom relief (10-13 days).
103 The reason for the differences in Tiberiu Hershcovici and Ronnie Fass
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therapeutic response parameters between NERD and erosive 
esophagitis is primarily due to the common inclusion of func-
tional heartburn subjects in the NERD group. However, be-
cause most NERD patients demonstrate only modest abnormal 
esophageal acid exposure, even after excluding functional heart-
burn patients, the symptomatic response rate of NERD patients 
to PPI remains lower that what has been observed in erosive 
esophagitis patients. 
Because GERD is mostly not a progressive disorder, treat-
ment for many of these patients could be symptom driven. Thus, 
on-demand or intermittent therapy with a PPI is an attractive 
therapeutic strategy for NERD patients in clinical practice.
104,105 
These therapeutic approaches are convenient, allow patients to 
remain in control, cost effective, and decrease the likelihood of re-
bound of acid secretion. Studies have demonstrated that inter-
mittent or on-demand PPI therapy in NERD is effective and as-
sociated with improved quality of life as well as reduced cost.
106,107 
Dexlansoprazole MR is a novel, modified-release for-
mulation of dexlansoprazole, which incorporates dual de-
layed-release technology designed to prolong the serum concen-
tration-time profile, and thus provides extended acid-sup-
pression, has been recently assessed in NERD patients. 
Dexlansoprazole 30 mg/day for 4 weeks was shown to be superior 
to placebo in providing 24-hour heartburn-free days and nights 
(54.9% vs. 17.5% and 80.8% vs. 51.7%, respectively).
108 
Novel therapeutic modalities are currently under consid-
eration for GERD patients and specifically those with NERD. 
The main areas of interest include improving acid suppression, 
reducing the transient lower esophageal sphincter relaxation rate, 
decreasing esophageal sensitivity, and enhancing esophageal 
motility. 
Response to antireflux surgery has been shown to be different 
between patients with NERD versus those with erosive 
esophagitis. Fenton et al. compared the clinical outcome of an-
ti-reflux surgery in patients with erosive esophagitis versus those 
with NERD, demonstrating that 91% versus 56% reported 
heartburn resolution, 24% versus 50% reported dysphagia 




NERD is the most common phenotypic presentation of 
GERD. Whilst separating between erosive esophagitis and 
NERD on a clinical level is a very difficult task, there are clearly 
physiological, pathophysiological, anatomical, and even histo-
logical characteristics that are unique to NERD. Natural course 
studies demonstrate that most NERD patients will not progress 
over time to erosive esophagitis or even Barrett’s oesophagus. 
NERD patients as compared to those with erosive esophagitis 
demonstrate a highly variable and unpredictable symptomatic re-
sponse rate to antireflux treatment. This is likely to explain the 
high percentage of NERD patients among those who failed PPI 
treatment. 
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